# Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer

> **NCT04030455** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 28 (actual)

## Conditions studied

- Laryngeal Squamous Cell Carcinoma
- Stage II Laryngeal Cancer AJCC v8
- Stage III Laryngeal Cancer AJCC v8

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04030455
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-07
- **Primary completion:** 2025-09-04
- **Final completion:** 2026-09-17
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04030455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04030455, "Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04030455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*